Business
Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors
(TheNewswire) TORONTO and BOSTON - September 22, 2025 - The Newswire — Serno...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n TORONTO and BOSTON - September 22, 2025 -\n \n\n The\n \n\n Newswire — Sernova Biotherapeutics\n(“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) a leading\nregenerative medicine company focused on developing its Cell Pouch\nBio-hybrid Organ as a functional cure for type 1 diabetes (T1D),\n \n\n today announced the appointment of John L.\nBrooks III as Chair of the Company’s Board of Directors.\n \n\n\n\n “We are honored to have John lead our Board at this\nexciting time for Sernova,” said Jonathan Rigby, CEO of Sernova.\n“His deep experience in T1D, venture capital and building\nearly-stage companies will be invaluable as we advance our Cell Pouch\nBio-hybrid Organ as a functional cure for T1D into the final cohort of\nour ongoing phase 1 / 2 clinical trial.”\n \n\n\n\n John L. Brooks III currently serves as Managing\nDirector at Healthcare Capital LLC, where he advises early-stage life\nscience companies and also as the CEO of Diamune that is developing\ninnovative IgG Fc-Fusion insulin analogs. During his career, Mr.\nBrooks served as the Chair and CEO of the Joslin Diabetes Center, the\nworld's preeminent diabetes research, clinical care, and\neducation organization. Additionally, he has co-founded seven life\nscience companies, including Insulet Corporation (Nasdaq; PODD),\ndeveloper of the Omnipod tubeless insulin pump. He was previously a\nfounder of Prism Venture Partners, a senior medical device executive\nat Pfizer, and a senior manager at Arthur Andersen & Co. Mr.\nBrooks also serves on the boards of several T1D and population health\norganizations.\n \n\n\n\n “I am thrilled to join Sernova at such an exciting\nmoment in its journey,” said Mr. Brooks. “The Cell Pouch\nBio-hybrid Organ holds great potential for patients with T1D, and the\nintegration of novel immunotherapies like tegoprubart could\nsignificantly improve the durability and effectiveness of islet cell\ntransplantation. I look forward to working with the leadership team\nand board to help guide Sernova as we seek to provide T1D patient...